Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Learn more about:
Related Clinical Trial
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492